Aster Capital Management DIFC Ltd Acquires New Shares in Moderna, Inc. (NASDAQ:MRNA)

Aster Capital Management DIFC Ltd bought a new position in shares of Moderna, Inc. (NASDAQ:MRNA) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund bought 11,987 shares of the company’s stock, valued at approximately $498,000.

Other institutional investors and hedge funds have also recently made changes to their positions in the company. Wilmington Savings Fund Society FSB grew its position in Moderna by 295.0% during the 4th quarter. Wilmington Savings Fund Society FSB now owns 786 shares of the company’s stock worth $33,000 after acquiring an additional 587 shares during the last quarter. Compass Planning Associates Inc bought a new stake in shares of Moderna during the fourth quarter worth about $37,000. Venturi Wealth Management LLC increased its stake in shares of Moderna by 286.2% in the fourth quarter. Venturi Wealth Management LLC now owns 896 shares of the company’s stock valued at $37,000 after buying an additional 664 shares during the period. Crowley Wealth Management Inc. acquired a new position in shares of Moderna in the fourth quarter valued at approximately $41,000. Finally, MassMutual Private Wealth & Trust FSB raised its holdings in Moderna by 58.2% in the 4th quarter. MassMutual Private Wealth & Trust FSB now owns 1,057 shares of the company’s stock valued at $44,000 after buying an additional 389 shares during the last quarter. Institutional investors own 75.33% of the company’s stock.

Analysts Set New Price Targets

A number of research firms have weighed in on MRNA. Barclays lowered shares of Moderna from an “overweight” rating to an “equal weight” rating and reduced their target price for the stock from $111.00 to $45.00 in a report on Tuesday, February 18th. Leerink Partners decreased their price objective on Moderna from $31.00 to $27.00 and set an “underweight” rating for the company in a report on Thursday, January 16th. Morgan Stanley cut their price objective on Moderna from $70.00 to $38.00 and set an “equal weight” rating on the stock in a research note on Wednesday, January 15th. The Goldman Sachs Group downgraded shares of Moderna from a “buy” rating to a “neutral” rating and lowered their target price for the stock from $99.00 to $51.00 in a research note on Wednesday, January 29th. Finally, Argus cut shares of Moderna from a “buy” rating to a “hold” rating in a research report on Wednesday, December 18th. Four analysts have rated the stock with a sell rating, sixteen have issued a hold rating, three have assigned a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average price target of $59.00.

Moderna Stock Performance

Shares of MRNA opened at $25.11 on Monday. The firm has a market capitalization of $9.71 billion, a P/E ratio of -2.71 and a beta of 2.23. Moderna, Inc. has a 52 week low of $23.76 and a 52 week high of $170.47. The stock has a 50 day moving average price of $33.55 and a two-hundred day moving average price of $42.61.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.